Tarsus Pharmaceuticals Stock Performance
| TARS Stock | USD 48.24 1.84 3.97% |
On a scale of 0 to 100, Tarsus Pharmaceuticals holds a performance score of 21. The entity has a beta of 0.83, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tarsus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tarsus Pharmaceuticals is expected to be smaller as well. Please check Tarsus Pharmaceuticals' downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to make a quick decision on whether Tarsus Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
21 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Tarsus Pharmaceuticals are ranked lower than 21 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Tarsus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.97 | Five Day Return 7.46 | Year To Date Return 139.29 | Ten Year Return 134.4 | All Time Return 134.4 |
1 | Acquisition by Link William J Phd of 27116 shares of Tarsus Pharmaceuticals subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 1333 shares by Morrison Scott W of Tarsus Pharmaceuticals subject to Rule 16b-3 | 09/13/2024 |
3 | Tarsus Pharmaceuticals, Inc.s Path To Profitability | 10/09/2024 |
4 | Head to Head Survey Tarsus Pharmaceuticals and Voyager Therapeutics | 10/15/2024 |
5 | Amicus Therapeutics Stock Jumps 14.0 percent Will It Continue to Soar | 10/18/2024 |
6 | Acquisition by Yarno Wendy L of 3350 shares of Tarsus Pharmaceuticals subject to Rule 16b-3 | 10/28/2024 |
7 | Acquisition by Lin Elizabeth Yeu of 27278 shares of Tarsus Pharmaceuticals subject to Rule 16b-3 | 11/04/2024 |
8 | Vanguard Group Incs Strategic Acquisition in Tarsus Pharmaceuticals Inc | 11/05/2024 |
9 | 2seventy bio, Inc. Reports Q3 Loss, Lags Revenue Estimates | 11/12/2024 |
10 | Tarsus Pharmaceuticals GAAP EPS of -0.61 beats by 0.31, revenue of 48.1M beats by 4.92M | 11/13/2024 |
11 | Tarsus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations | 11/15/2024 |
12 | Mutual of America Capital Management LLC Invests 4.29 Million in Tarsus Pharmaceuticals, Inc. - MarketBeat | 11/22/2024 |
| Begin Period Cash Flow | 71.7 M | |
| Free Cash Flow | -123 M |
Tarsus |
Tarsus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,699 in Tarsus Pharmaceuticals on August 27, 2024 and sell it today you would earn a total of 2,125 from holding Tarsus Pharmaceuticals or generate 78.73% return on investment over 90 days. Tarsus Pharmaceuticals is currently generating 0.9709% in daily expected returns and assumes 3.5286% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Tarsus, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tarsus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tarsus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tarsus Pharmaceuticals, and traders can use it to determine the average amount a Tarsus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2751
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TARS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.53 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.97 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.28 actual daily | 21 79% of assets perform better |
Based on monthly moving average Tarsus Pharmaceuticals is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tarsus Pharmaceuticals by adding it to a well-diversified portfolio.
Tarsus Pharmaceuticals Fundamentals Growth
Tarsus Stock prices reflect investors' perceptions of the future prospects and financial health of Tarsus Pharmaceuticals, and Tarsus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tarsus Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (0.52) % | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 38.23 M | ||||
| Price To Book | 7.76 X | ||||
| Price To Sales | 14.23 X | ||||
| Revenue | 17.45 M | ||||
| Gross Profit | (17.76 M) | ||||
| EBITDA | (131.67 M) | ||||
| Net Income | (135.89 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 31.73 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 6.22 X | ||||
| Cash Flow From Operations | (117.49 M) | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 1.84 B | ||||
| Total Asset | 265.49 M | ||||
| Retained Earnings | (244.66 M) | ||||
| Working Capital | 219.19 M | ||||
About Tarsus Pharmaceuticals Performance
Assessing Tarsus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Tarsus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tarsus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 711.90 | 701.51 | |
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.63) | (0.66) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.69) | (0.66) |
Things to note about Tarsus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Tarsus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tarsus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tarsus Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 17.45 M. Net Loss for the year was (135.89 M) with loss before overhead, payroll, taxes, and interest of (17.76 M). | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (117.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Tarsus Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Mutual of America Capital Management LLC Invests 4.29 Million in Tarsus Pharmaceuticals, Inc. - MarketBeat |
- Analyzing Tarsus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tarsus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Tarsus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tarsus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tarsus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tarsus Pharmaceuticals' stock. These opinions can provide insight into Tarsus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.